{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:16:52Z","timestamp":1789881412252,"version":"4.0.1"},"reference-count":13,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,1,14]],"date-time":"2003-01-14T00:00:00Z","timestamp":1042502400000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Headache"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background<\/jats:bold>\n                    Little information exists about the actual prescription of triptans within large, geographically diverse populations, in terms of demographic characteristics and co\u2010prescriptions with other medications with potential interactions.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objectives<\/jats:bold>\n                    To investigate the demographic characteristics associated with triptan use, and examine the rate of co\u2010prescription of triptans with specified pharmacologic agents with the potential for drug interactions.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    This study examined the rate of co\u2010prescription of triptans available in the US up to May 2001 (sumatriptan, naratriptan, rizatriptan, and zolmitriptan) with specified agents with potential for drug interactions. A cohort of 240,268 patients receiving pharmacy benefits from Merck\u2010Medco (N\u2003\u2003=\u2003\u200365\u2003\u2003+\u2003\u2003M) was followed over a one\u2010year period. This analysis included patients who received at least two triptan prescriptions during the study (6\/00\u20105\/01). Ninety\u2010one percent of the cohort remained on the same triptan during the study period. \u2018Co\u2010prescription\u2019 was defined as any fill for a medication that was contraindicated or could potentially adversely interact with a triptan, obtained between and during the first and last triptan fills throughout the study period.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    Mean patient age was 43 (SD\u2003\u2003\u00b1\u2003\u200311.6) and 82% were female. Twenty\u2010one percent were co\u2010prescribed selective serotonin reuptake inhibitors, reflecting the considerable co\u2010morbidity of migraine and depression. Patients taking triptans were almost never co\u2010prescribed monoamine oxidase inhibitors (0.02%), and co\u2010prescription of ergots was also low (1.45%). Less than one percent (0.45%) received cimetidine while taking zolmitriptan, while 2.7% of patients taking rizatriptan 10 mg also took propranolol. While agents unavailable in the U.S. were not evaluated in this cohort, six percent of patients were treated with potent CYP 3A4 inhibitors, which would not be expected to cause any problems with the triptans in the survey. However, such agents are specifically contraindicated for use with one triptan (eletriptan), recently launched in the EU, suggesting that continued vigilance will be necessary to avoid coprescription of medicines with the potential for producing adverse side effects.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                    Triptan use mirrors migraine demographics. The frequency of co\u2010prescription of triptans with SSRIs is about 20%. Continued vigilance will be necessary to avoid co\u2010prescription of medicines with the potential for producing adverse drug events.\n                  <\/jats:p>","DOI":"10.1046\/j.1526-4610.2003.03007.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T18:20:22Z","timestamp":1047406822000},"page":"44-48","source":"Crossref","is-referenced-by-count":49,"title":["Coprescription of Triptans With Potentially Interacting Medications: A Cohort Study Involving 240\u2003268 Patients"],"prefix":"10.1111","volume":"43","author":[{"given":"Stewart","family":"Tepper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Boccuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,1,14]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"2","article-title":"Migraine headaches: epidemiology and comorbidity.","volume":"5","author":"Lipton RB","year":"1998","journal-title":"Clin Neurosci"},{"key":"e_1_2_6_3_2","unstructured":"U.S. Census data.http:\/\/www.census.gov\/ftp\/pub\/population\/www."},{"key":"e_1_2_6_4_2","unstructured":"U.S. labeling information for naratriptan rizatriptan sumatriptan and zolmitriptan. 2001 Physician's Desk Reference. Montvale NJ: Thomas Healthcare; 2001."},{"key":"e_1_2_6_5_2","unstructured":"Summaries of product characteristics for eletriptan naratriptan rizatriptan sumatriptan and zolmitriptan. Electronic Medicines Compendium.http:\/\/emc.vhn.net."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.38.1.389"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03830.x"},{"key":"e_1_2_6_8_2","first-page":"408","article-title":"Patient reported tablet utilization of zolmitriptan and sumatriptan.","volume":"38","author":"Tepper SJ","year":"1998","journal-title":"Headache"},{"key":"e_1_2_6_9_2","first-page":"411","article-title":"Prospective study on triptan tablet consumption per attack in Spain.","volume":"20","author":"Pascual J","year":"2000","journal-title":"Cephalalgia"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.5.629"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370004501008"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1999.019007668.x"},{"key":"e_1_2_6_13_2","first-page":"431","article-title":"Concomitant eletriptan and selective serotonin reuptake therapy for migraine patients: a review of seven clinical studies.","volume":"21","author":"Hettiarachchi J","year":"2001","journal-title":"Cephalalgia"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920030-00007"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1526-4610.2003.03007.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1526-4610.2003.03007.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:26:18Z","timestamp":1762079178000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1046\/j.1526-4610.2003.03007.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1046\/j.1526-4610.2003.03007.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1526-4610.2003.03007.x","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}